Search
Primary Sclerosing Cholangitis Clinical Trials
A listing of 16 Primary Sclerosing Cholangitis clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 16 of 16
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Primary Sclerosing Cholangitis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 16 active clinical trials seeking participants for Primary Sclerosing Cholangitis research studies. The states with the highest number of trials for Primary Sclerosing Cholangitis participants are California, Virginia, Texas and Florida.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Characterization of Biliary Cell-derived Organoids from Bile of PSC and Non-PSC Patients
Recruiting
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/10/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
A Study of SIPLIZUMAB in AILD and LT Patients
Recruiting
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York
Conditions: Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
Recruiting
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC.
We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.
Gender:
ALL
Ages:
Between 15 years and 80 years
Trial Updated:
04/19/2024
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Primary Sclerosing Cholangitis
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Recruiting
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Gender:
ALL
Ages:
Between 2 weeks and 40 years
Trial Updated:
11/10/2016
Locations: Sacramento Pediatric Gastroenterology, Sacramento, California
Conditions: Primary Sclerosing Cholangitis, Biliary Atresia
13 - 16 of 16